WCPO: Eyes are the focus of new University of Cincinnati study to treat PTSD
Kate Chard, PhD, UC professor of psychiatry and behavioral neuroscience.
Eyes are the focus of a new study to help heal combat veterans of their post-traumatic stress tied to their service.
Kate Chard, PhD, UC professor of psychiatry and behavioral neuroscience and director of PTSD programs at the Cincinnati Department of Veterans Affairs Medical Center, spoke with WCPO about a study examining the effectiveness of Eye Movement Desensitization and Reprocessing to Cognitive Processing Therapy.
A $1.25 million donation from PESI, one of the world’s largest providers of mental health continuing education, is funding the three-year study.
“This therapy allows you to think of all the things that you don't want to tell anyone, even your best combat friend, and it allows you to keep all of that private, and you can still get better and not have those memories control you in the future,” Chard said.
Featured image at top: CARE/Crawley building. Photo/Chris Radcliffe for the UC Foundation
Next Now
With its focus on innovation and impact, Next, Now: The Campaign for Cincinnati is where ambition meets action. At the University of Cincinnati and UC Health, we’re driven by next; thinking bolder and dreaming bigger to create the tomorrow we envision, today. Learn more at nextnow.uc.edu.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.